FundaMental Pharma appoints Dr. Dirk Beher as Chief Executive Officer
April 11, 2024 07:00 ET
|
Fundamental Pharma GmbH
PRESS RELEASE FundaMental Pharma appoints Dr. Dirk Beher as Chief Executive Officer Highly experienced biotech executive, with over a quarter of a century of CNS drug discovery experienceDr. Beher...
Alumis Presents Preclinical Data for Allosteric TYK2 Inhibitor A-005 at ACTRIMS
March 01, 2024 08:00 ET
|
Alumis Inc
– A-005 is a potential first-in-class, brain penetrant TYK2 inhibitor for the treatment of neuroinflammatory and neurodegenerative diseases – – Data support planned Phase 1 clinical trial on track to...
Automated Fare Collection (AFC) System Market projected to reach USD 27 Billion by 2030, growing at a CAGR of 12.86% during the forecast period of 2023-2030 - pronounced by MarketDigits in its recent study
February 05, 2024 11:00 ET
|
PIONEERING MARKETDIGITS CONSULTING AND ADVISORY PRIVATE LIMITED
Richmond, Feb. 05, 2024 (GLOBE NEWSWIRE) -- According to a research report "Automated Fare Collection (AFC) System Market”, by Components Type (Hardware, software, Others), Application (Automatic...
Stem Cell Assays Market Size & Share to Surpass USD 8.5 billion by 2033 | Analysis by Transparency Market Research
January 18, 2024 09:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global stem cell assays market is estimated to flourish at a CAGR of 16.5% from 2023 to...
Smart highway Market Size Worth USD 116.46 Billion in 2032 | Emergen Research
January 08, 2024 08:57 ET
|
Emergen Research
Vancouver, Jan. 08, 2024 (GLOBE NEWSWIRE) -- The global smart highway market size was USD 20.90 Billion in 2022 and is expected to register a rapid revenue CAGR of 18.7% during the forecast period....
Ractigen Presents Preclinical Results of Its saRNA Therapeutic Targeting DMD/BMD at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting
November 02, 2023 08:00 ET
|
Ractigen Therapeutics
Ractigen Presents Preclinical Results of Its saRNA Therapeutic Targeting DMD/BMD at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting
Vyant Bio Announces Stockholder Approval of Proposed Asset Sale; 64,110 Votes Needed to Approve Plan of Dissolution; and Adjournment of Special Meeting of Stockholders
October 19, 2023 11:45 ET
|
Vyant Bio, Inc.
CHERRY HILL, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT) announced that its special meeting of stockholders on October 19, 2023 (the “Special...
Silo Pharma’s SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis
October 16, 2023 08:11 ET
|
Silo Pharma, Inc.
Human tissue study assessed SPU-21’s efficiency, optimization, and binding affinity ENGLEWOOD CLIFFS, NJ, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a...
Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day
October 02, 2023 13:17 ET
|
Praxis Precision Medicines, Inc.
Positive results from preliminary analysis of PRAX-222 Part 1 showed 44% median reduction in seizures after three doses for SCN2A-gain-of-function pediatric patients Phase 3 (Essential3) program for...
Vyant Bio Announces Adjournment of Special Meeting of Stockholders
September 28, 2023 11:45 ET
|
Vyant Bio, Inc.
CHERRY HILL, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT), today announced that its special meeting of stockholders on September 28, 2023 (the...